Brief: Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee
03/04/2025 13:06
April 3 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY EVALUATING SAFETY AND EFFICACY OF PCRX-201 FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE PACIRA BIOSCIENCES INC - TOPLINE RESULTS EXPECTED LATE 2026 Source text: ID:nGNX5VPhJq Further company coverage: PCRX.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal